Clinical and Autoantibody Associations in Antinuclear Antibody–Positive Systemic Sclerosis Lacking Prototypic Autoantibodies

Kruzer, Karen; Marangoni, Roberta Gonçalves; Heckler, Ilana; Elhage, Aya; Varga, John; Hinchcliff, Monique; Carns, Mary; Aren, Kathleen; Wielgosz, Amy; Nuzzo, Marc; Venkataraman, Iswariya; Korman, Benjamin

doi:10.1097/rhu.0000000000001881

Cited by 4 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The sensitivity of SSP obtained is consistent with the range of 71-85% reported previously by other authors [7,8,14]. Here, we demonstrated SSP's usefulness in detecting SSc-related antibodies in triple-negative patients (negative for ATA, ACA, and RNAP), a term used by Kruzer et al [64]. Their recent study concluded that triple-negative SSc patients should undergo testing with an immunoblot assay like SSP because they have a higher risk of SSc-ILD and myopathy.…”

Section: Clinical Usefulness Of Systemic Sclerosis Profile (Ssp)supporting

confidence: 92%

Autoantibodies and Clinical Correlations in Polish Systemic Sclerosis Patients: A Cross-Sectional Study

Żebryk

Przymuszała

Nowak

et al. 2023

JCM

View full text Add to dashboard Cite

We evaluated the prevalence of systemic sclerosis (SSc)-related autoantibodies and their clinical significance and compared the sensitivity of two line immunoblot assays on a prospective study group of 96 Polish SSc patients (ACR-EULAR 2013 criteria) whose sera were assessed by indirect immunofluorescence (HEp-2 and monkey liver) and line immunoblot assays: ANA Profile 3 and Systemic Sclerosis Profile by EUROIMMUN (Lübeck, Germany). Organ involvement was evaluated according to the EUSTAR Minimal Essential Data Set. The following autoantibodies’ prevalence was found: Scl-70 (36%), Ro-52 (28%), CENP-B (22%), CENP-A (20%), PM-Scl-75 (20%), PM-Scl-100 (14%), fibrillarin (7%), Th/To (7%), RNA polymerase III 11 kDa (5%), RNA polymerase III 155 kDa (3%), PDGFR (3%), NOR-90 (2%), and Ku (1%). Significant associations between the autoantibodies’ presence and organ involvement were found: ATA (dcSSc > lcSSc, less prevalent muscle weakness), Ro-52 (gangrene, DLCO < 60), CENP-B and A (lcSSc > dcSSc, normal CK), CENP-B (rarer digital ulcers and joint contractures), PM-Scl-100 and 75 (PM/SSc overlap, CK increase, muscle weakness, muscle atrophy), PM-Scl-100 (dcSSc unlikely), PM-Scl-75 (lung fibrosis), fibrillarin (muscle atrophy, proteinuria, conduction blocks, palpitations), Th/To (proteinuria, arthritis, muscle weakness, and rarer esophageal symptoms), RNA Polymerase III 11 kDa (arterial hypertension, renal crisis), RNA polymerase III 155 kDa (renal crisis), and PDGFR (dcSSc, tendon friction rubs). Additionally, the Systemic Sclerosis Profile was significantly more sensitive in detecting SSc-related autoantibodies than ANA Profile 3 (p = 0.002). In conclusion, individual autoantibodies associated with specific characteristics of SSc.

show abstract

Section: Clinical Usefulness Of Systemic Sclerosis Profile (Ssp)supporting

confidence: 92%

Autoantibodies and Clinical Correlations in Polish Systemic Sclerosis Patients: A Cross-Sectional Study

Żebryk

Przymuszała

Nowak

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…I read Kruzer and colleagues' 1 interesting article on triple-negative systemic sclerosis patients. I was intrigued to note that line immunoblot (LIB) autoantibody intensity categories were arbitrated with suitable positive and negative controls (“positive and negative controls were used to identify the intensity…” under Methods).…”

mentioning

confidence: 99%

Borderline or Weak Positive Autoantibodies in Line Immunoblots

Lee¹

2022

J Clin Rheumatol

View full text Add to dashboard Cite

Les anticorps antinucléaires : spectateurs ou acteurs ? Exemple de la sclérodermie systémique

Chépy,

Collet,

Sobanski

et al. 2024

Revue Francophone des Laboratoires

View full text Add to dashboard Cite

Clinical and Autoantibody Associations in Antinuclear Antibody–Positive Systemic Sclerosis Lacking Prototypic Autoantibodies

Cited by 4 publications

References 15 publications

Autoantibodies and Clinical Correlations in Polish Systemic Sclerosis Patients: A Cross-Sectional Study

Autoantibodies and Clinical Correlations in Polish Systemic Sclerosis Patients: A Cross-Sectional Study

Borderline or Weak Positive Autoantibodies in Line Immunoblots

Les anticorps antinucléaires : spectateurs ou acteurs ? Exemple de la sclérodermie systémique

Contact Info

Product

Resources

About